Biotech Floods the August IPO Window While the SEC Rethinks 20 Years of Market Structure

The IPO market is doing something it has not done in years: broadening. For most of 2026, new issuance has been dominated by AI infrastructure and a handful of mega-listings. That pattern held through July, when eight IPOs raised a combined $29.3 billion — more than six times the month’s 10-year historical average — but almost entirely because of a single deal^[1]. The first week of August told a different story: six IPOs priced, five of them biotech, with deal sizes ranging from $150 million to $383 million and no single name dominating the tape^[2].

That shift from concentration to breadth matters. It suggests the IPO window is opening wider than the AI-infrastructure narrative alone can explain, and it arrives at the same moment the SEC is proposing the most significant change to US equity market structure in two decades.

July: A Mega-Listing Disguised a Thin Market

SK hynix (SKHY) raised $26.5 billion in its July 10 Nasdaq listing — the largest US equity offering from a foreign issuer in history^[3]. The South Korean memory-chip giant’s ADRs rose 13% on the first day, closing at $168.01^[3]. Strip that deal out, and July’s remaining seven IPOs raised less than $3 billion combined. Renaissance Capital noted that the month’s total deal count of eight came in well below the historical mean of 20 IPOs, with persistent volatility from AI spending fears and geopolitical tensions holding back flow^[1].

Jersey Mike’s (JMKE) was the month’s other headline deal. The Blackstone-backed sandwich chain raised $1 billion at $23 per share — the midpoint of its $21 to $25 range — giving it an initial valuation of roughly $7.3 billion^[4]. Blackstone had owned the company for only about 18 months, making it one of the fastest PE-to-IPO flips in recent memory^[4]. The market was unimpressed: shares opened at $21 and closed at $21.63, down roughly 6% from the offer price^[4].

The muted reception for a profitable, asset-light franchise business is worth noting. If a consumer name with real unit economics and strong average unit volumes cannot hold its offer price, the bar for less mature consumer issuers may be higher than the pipeline assumes.

August: Biotech Takes the Baton

The first week of August reversed July’s concentration problem. Six IPOs priced, five in biotech, and the returns were surprisingly strong for a sector often dismissed as binary:

Source: Renaissance Capital weekly recap, August 7, 2026^[2].

Braveheart Bio (BRVE) was the standout: it upsized, priced above the range, and finished its first week up 67%^[2]. The cardiovascular biotech is developing an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy, with a Phase 3 trial planned for the second half of 2026^[2]. Latigo Therapeutics (LTGO), which is advancing a non-opioid pain drug with Phase 3 trials also planned for 2H26, raised $346 million^[2]. Attovia Therapeutics (ATTO) raised $289 million for its immune-disease pipeline and finished the week up 19%^[2].

What stands out is that several of these deals upsized or priced at the top of their ranges — a sign that underwriter demand was genuine rather than manufactured. The one exception was River City Bank (RCBC), a Northern California commercial lender that downsized and priced below the range, and Ticketplus (TP), a small Latin American ticketing platform that priced at the bottom and traded down 13%^[2]. The market is rewarding clinical-stage biotech with credible near-term catalysts but is not indiscriminately buying everything.

Five SPACs also priced during the week, raising a combined $605 million, and eight more filed initial S-1s^[2]. SPAC issuance has been quietly rebuilding through 2026 after nearly vanishing in 2023-2024, though the deal sizes remain modest.

The Bigger Picture: 1H26 Was the Strongest First Half Since 2021

Global ECM issuance reached $729.4 billion in the first half of 2026, the highest 1H volume since 2021, driven heavily by the record-breaking SpaceX IPO^[5]. Morgan Stanley reported that global issuance rose 43% year over year to $256.8 billion in Q1 alone, with IPO volumes up 40% to $45 billion^[6]. The pipeline is skewing larger and later-stage, reflecting years of private capital formation that let companies build scale before going public^[6].

Financial sponsors are central to this supply. PE-backed IPOs have represented roughly a third of US listings recently, and PE-backed issuance reached $12.8 billion in Q3 2025 alone — the strongest quarter since 2022^[6]. Morgan Stanley’s Eddie Molloy noted that investor demand spans “the entire ecosystem — service providers, power infrastructure, industrial components — everything required to support that growth,” rather than just data centers^[6].

EY’s Q2 2026 Global IPO Trends report struck a similar note, describing 1H activity as strong enough to set the stage for “what could be a historic 2H 2026,” while cautioning that execution windows “may be episodic and could be shaped by mega-IPOs and geopolitics”^[5].

The Renaissance IPO Index was up 18.8% year-to-date as of August 6, outpacing the S&P 500’s 13.4% gain, though it sank 14% in July alone as rotation out of tech and AI infrastructure names accelerated^[2][1]. The International IPO Index was up 40.0% year-to-date, reflecting the SK hynix effect^[2].

The Quiet Story: SEC Proposes Rescinding the Trade-Through Rule

All of this issuance runs on market plumbing that the SEC may be about to overhaul. On June 11, 2026, the Commission proposed rescinding Rule 611 of Regulation NMS — the trade-through prohibition that has required trading centers to execute orders at the best displayed price across all venues since 2005 — along with Rule 610(e), which restricts locking and crossing quotations^[7].

Chairman Paul Atkins framed the proposal as simplification: “After two decades of Rule 611, it is high time that the Commission review its unintended consequences that have hindered — rather than enhanced — the long-term growth of our markets”^[7]. Commissioners Mark Uyeda and Hester Peirce both issued supportive statements, with Uyeda calling it “an important beginning in the broader, more complex journey of reforming the Commission’s equity market structure rules”^[8].

The scope is significant. According to the SEC’s own estimates, 305 trading centers are currently subject to Rule 611, including 20 exchanges, 33 ATSs, 96 exchange market makers, and 225 broker-dealers^[9]. The rule has been the backbone of the order-protection regime that shaped the rise of maker-taker pricing, payment for order flow, and the fragmented exchange-and-dark-pool architecture of US equities for two decades.

The base-rate question is whether removing trade-through protection would meaningfully change execution quality for investors. Proponents argue that modern high-speed routing and competing execution venues make the rule redundant, and that its rescission would lower costs and encourage venue competition. Skeptics counter that without the rule, smaller orders could more easily be executed at inferior prices, particularly in less liquid names — exactly the kind of small-cap and biotech stocks that dominate the current IPO calendar. A 60-day public comment period is open^[7], and any final rule would likely take effect in 2027 at the earliest.

What to Watch Next

1. The IPO summer pause and its aftermath. Renaissance Capital expects several deals to slip in before the market’s annual late-August slowdown^[1]. The pace of new filings — two IPOs and eight SPACs in the first week of August alone^[2] — suggests the pipeline is not emptying. The question is whether post-Labor-Day issuance can sustain the biotech momentum or whether the window narrows again if volatility returns.

2. Consumer-deal reception as a signal of breadth. Jersey Mike’s broke the AI-and-biotech pattern in July but traded below its offer price. If upcoming consumer or retail names meet similar resistance, the market’s “broadening” narrative weakens. If they succeed, it strengthens.

3. The NMS comment docket. The 60-day comment window on the Rule 611 rescission will likely produce submissions from exchanges, market makers, institutional investors, and retail-brokerage advocates. The tone and volume of comments will signal how contentious a final rulemaking could be — and whether the timeline slips past 2027.

4. Renaissance IPO Index direction after July’s 14% drop. The index is still ahead of the S&P 500 year-to-date^[2], but a second consecutive down month would mark a trend, not a blip, and could cool issuer enthusiasm for the fall calendar.

5. SPAC pipeline rebuilding. Eight new SPAC filings in a single week^[2] is a level not seen since 2021. Whether these vehicles find targets — and whether investors keep funding them — will be a lagging indicator of risk appetite for less-proven business models.

FN2 Research provides market commentary and education, not personalized investment advice. All figures are sourced from publicly available information at the time of writing.